Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.64 |
| ▸ | CXCR1 | P25024 | 4/20 | 0.64 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.64 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.64 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.64 |
| ▸ | ALB | P02768 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
| ▸ | RARB | P10826 | 1/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393183 | 1.00 | PTGS2 (0.64) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL1345158 | 1.00 | PTGS2 (0.64) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL66534 | 1.00 | PTGS2 (0.64) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL4264095 | 0.88 | TAAR1 (0.53) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL15295486 | 0.88 | TAAR1 (0.53) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL15295485 | 0.88 | TAAR1 (0.53) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL9015267 | 0.85 | LMNA (0.50) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL9425565 | 0.84 | PTGS2 (0.56) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL3674499 | 0.84 | PTGS2 (0.69) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL4943395 | 0.83 | PTGS2 (0.51) | PTGS2PTGS1CXCR1CXCR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229942-B1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPE SPA (IT) | 2012-08-29 | — | — | EP | disclosed |
| EP-1638505-B1 | AMPHIPHILIC PYRIDINIUM COMPOUNDS, METHOD OF MAKING AND USE THEREOF | JACKSON H M FOUND MILITARY MED (US) | 2012-04-25 | — | — | EP | disclosed |
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | disclosed |
| US-8063242-B2 | for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion | DOMPE PHA.R.MA S.P.A. (IT) | 2011-11-22 | — | — | US | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| US-7893094-B2 | Amphiphilic pyridinium compounds, method of making and use thereof | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2229942-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | Dompe S.p.A. (IT) | 2010-09-22 | — | — | EP | disclosed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
| EP-1638505-A4 | AMPHIPHILIC PYRIDINIUM COMPOUNDS, METHOD OF MAKING AND USE THEREOF | JACKSON H M FOUND MILITARY MED (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20070105916-A1 | Amphiphilic pyridinium compounds, method of making and use thereof | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 2007-05-10 | — | — | US | disclosed |
| EP-1638505-A2 | AMPHIPHILIC PYRIDINIUM COMPOUNDS, METHOD OF MAKING AND USE THEREOF | HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2005-02-17 | — | — | US | disclosed |
| WO-2005002519-A2 | AMPHIPHILIC PYRIDINIUM COMPOUNDS, METHOD OF MAKING AND USE THEREOF | HENRY M.JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | PTGS2 480/4885PTGS1 346/4885CXCR1 1912/4885 |
| US-20070105916-A1 | Amphiphilic pyridinium compounds, method of making and use thereof | CXCL8, IL18, CCR8 | PTGS2 544/4885PTGS1 421/4885CXCR1 213/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | PTGS2 480/4885PTGS1 346/4885CXCR1 1912/4885 |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | CXCR2, FPR1, CCR2 | PTGS2 99/4885PTGS1 88/4885CXCR1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.